French biotech Abivax reported positive results from two Phase 3 trials of obefazimod, an oral microRNA-124 enhancer for moderately to severely active ulcerative colitis patients. The 50 mg dose achieved a pooled 16.4% placebo-adjusted clinical remission rate at eight weeks with a favorable safety profile. This efficacy surpasses earlier trial data. The company is conducting a maintenance study and plans regulatory filings in the second half of 2026. Investor enthusiasm sent Abivax shares soaring over 500% on major exchanges.